Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 4Tumor-Agnostic 3Lymphoid 3Thoracic 2Other hematologic neoplasm 2Other 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Diphenhydramine × Tumor-Agnostic × Clear all
NCT03324113 2025-08-05

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Sanofi

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

NCT02648490 2019-07-30

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Henlix, Inc

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Eli Lilly and Company

Phase 2 Completed
68 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡